Zhuhai Rundu Pharmaceutical Co., Ltd.

002923

CNE1000033G8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 14/05/2024 BST			5-day change	1st Jan Change
11.04 ^CNY	-1.16%		-3.16%	-10.53%

04-27	Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-27	Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021

May 12, 2022 at 08:37 pm

Zhuhai Rundu Pharmaceutical Co., Ltd. approved at its AGM held on 11 May 2022 cash dividend/10 shares (tax included) of CNY 4.00000000 for the year 2021 at its AGM held on 11 May 2022.

Latest news about Zhuhai Rundu Pharmaceutical Co., Ltd.

Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-26	CI
Rundu Pharmaceutical's Rabeprazole Sodium Tablets Chosen for China's Centralized Procurement	11-09	MT
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	26/10/23	CI
Zhuhai Rundu Pharma Gets Supplementary Application Approval For Hypertension Drug	26/07/23	MT
Rundu Pharmaceutical Gets Nod to Market Raw Drug Material	13/07/23	MT
Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Final Cash Dividend for 2022, Payable on 31 May 2023	19/05/23	CI
Tianyu Pharmaceutical Unit Gets Approval to Market Hypertension Drug in China	09/05/23	MT
Zhuhai Rundu Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2022	27/04/23	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	26/04/23	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Management Appointments	15/03/23	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	26/10/22	CI
Rundu Pharmaceutical Unit Wins Drug Production License	04/10/22	MT
Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021	12/05/22	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Proposes Cash Dividend for 2021	20/04/22	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	19/04/22	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	18/04/22	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	25/10/21	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Dividend for 2020, Payable on 28 May 2021	19/05/21	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Announces Final Dividend Profit Distribution Proposal for 2020	23/04/21	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Announces to Implement Final Cash Distribution Plan for 2019, Payable on 09 June 2020	02/06/20	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Cash Dividend	18/05/20	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Proposes Final Cash Dividend on A Share for 2019	17/04/20	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Approves Election of Directors	31/03/20	CI
Zhuhai Rundu Pharmaceutical Co., Ltd. Announces 2018 Final Distribution Plan of (A Shares), Payable on 12 June 2019	03/06/19	CI

Chart Zhuhai Rundu Pharmaceutical Co., Ltd.

Duration

Period

Chart Zhuhai Rundu Pharmaceutical Co., Ltd.

More charts

Zhuhai Rundu Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and sales of chemical medicine preparations, chemical medicine raw materials and pharmaceutical intermediates. The Companyâs products cover the fields of cardio-cerebral blood vessels, digestion and anesthesia, among others.

Sector

Pharmaceuticals

Calendar

17/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHUHAI RUNDU PHARMACEUTICAL CO., LTD.	-10.53%	517M
NOVO NORDISK A/S	+31.37%	588B
JOHNSON & JOHNSON	-2.79%	364B
MERCK & CO., INC.	+20.39%	326B
ABBVIE INC.	+5.47%	285B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	210B
ROCHE HOLDING AG	-6.95%	200B
AMGEN INC.	+10.90%	167B
PFIZER, INC.	+0.02%	161B